One event. Multiple sources.
Business

Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss

1 publisher first detected 2% of 42 Business publishers

Headline as filed by Business Insider.

Compare coverage — 1 report

Every publisher that filed on this event, earliest first, with each one's headline, summary, times and how long after the first report they filed.
Publisher Headline Summary Published Detected Delay Source Status
Business Insider Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
In the first head-to-head trial of Ozempic versus Eli Lilly's new "King Kong" drug retatrutide, the next-generation drug led to more weight loss.
0m businessinsider.com First

Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.

Reader comments

Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.

Nobody has commented on this story yet.

Add a comment

Up to 2,000 characters. Links are not accepted. Blank lines separate paragraphs.

In this story
Eli Lilly 7 Ozempic 5

Related coverage

connected by shared subjects